Journal
NATURE REVIEWS DRUG DISCOVERY
Volume 7, Issue 3, Pages 221-230Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrd2519
Keywords
-
Funding
- EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U19HD077693] Funding Source: NIH RePORTER
- NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016480] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI066569] Funding Source: NIH RePORTER
- NCRR NIH HHS [P20 RR016480, P20 RR016480-07] Funding Source: Medline
- NIAID NIH HHS [U01AI066,569, U01 AI066569, U01 AI066569-03] Funding Source: Medline
- NICHD NIH HHS [U19 HD077693] Funding Source: Medline
- PHS HHS [N01A000,064] Funding Source: Medline
Ask authors/readers for more resources
Although genetic studies have been critically important for the identification of therapeutic targets in Mendelian disorders, genetic approaches aiming to identify targets for common, complex diseases have traditionally had much more limited success. However, during the past year, a novel genetic approach - genome-wide association ( GWA) - has demonstrated its potential to identify common genetic variants associated with complex diseases such as diabetes, inflammatory bowel disease and cancer. Here, we highlight some of these recent successes, and discuss the potential for GWA studies to identify novel therapeutic targets and genetic biomarkers that will be useful for drug discovery, patient selection and stratification in common diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available